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In a classical view of hematopoiesis, the various blood cell lineages arise via a 
hierarchical scheme starting with multipotent stem cells that become increasingly 
restricted in their differentiation potential through oligopotent and then unipotent 
progenitors. We developed a cell-sorting scheme to resolve myeloid (My), erythroid (Er), 
and megakaryocytic (Mk) fates from single CD34+ cells and then mapped the progenitor 
hierarchy across human development. Fetal liver contained large numbers of distinct 
oligopotent progenitors with intermingled My, Er and Mk fates.  However, few 
oligopotent progenitor intermediates were present in the adult bone marrow. Instead 
only two progenitor classes predominate, multipotent and unipotent, with Er-Mk 
lineages emerging from multipotent cells. The developmental shift to an adult ‘two-tier’ 
hierarchy challenges current dogma and provides a revised framework to understand 
normal and disease states of human hematopoiesis.  
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For decades, both human and mouse hematopoiesis has been described as a cellular hierarchy 
maintained by self-renewing hematopoietic stem cells (HSCs) that reside at the apex of its 
pyramidal structure of differentiating cells (1, 2). This differentiation scheme highlights key 
features of the blood hierarchy that has been critical to our understanding of how stem cells 
manage life-long blood production. In general, self-renewing cell types with extended lifespan 
like long term HSC (LT-HSC), as well as short-term HSC (ST-HSC) and multipotent 
progenitors (MPPs) are rare and remain closer to the conceptual peak of the hierarchy; 
oligopotent and unipotent progenitors farther down the scheme have shorter lifespans, increase 
numerically, and ultimately differentiate into more than ten functional blood cell types. In the 
standard model of hematopoiesis, hierarchical differentiation commences from HSCs with the 
production of stem cell intermediates with less durable self-renewal potential that culminate 
with the generation of MPPs, the penultimate step before lineage specification. From MPPs, 
the common lineages for myelopoiesis (common myeloid progenitor – CMP) and lymphopoiesis 
(common lymphoid progenitor – CLP) are segregated. In myeloid (My – defined herein as 
granulocyte/monocyte) differentiation, oligopotent CMPs undergo further restriction into 
bivalent granulocyte-monocyte progenitor (GMPs) that go on to make granulocytes and 
monocytes, and megakaryocyte-erythroid progenitors (MEPs) that go on to make platelets and 
red blood cells (RBCs). Thus, CMPs represent the critical oligopotent progenitor from which 
all My, erythroid (Er), and megakaryocyte (Mk) cells arise. Although the standard model is 
still used extensively as an operational paradigm, further cell purification and functional 
clonal assays have led to key revisions to the model. In mouse, the identification of lymphoid-
primed multipotent progenitors (LMPP) argued that megakaryocyte-erythroid (Mk-Er) 
potential must be the first lineage branch lost in lympho-myeloid specification of HSCs (3, 4). 
Recently, paired-daughter analysis monitoring of mouse HSC cell divisions have demonstrated 
that Mk-Er progenitors can be derived from HSC directly without progressing through 
conventional MPPs and CMPs (5). Although these data challenge the standard model, clear 
consensus on a revised model of hematopoiesis is still lacking. Human hematopoiesis is widely 
regarded as following the same differentiation scheme as mouse hematopoiesis (reviewed in 
(6)). Early work involving cell purification and methylcellulose (MC) colony-forming cell (CFC) 
assays yielded an identical scheme as the mouse including CMP and CLP (7-10). However, 
purification schemes to resolve My, Er, Mk and lymphoid (Ly) fates remained poor. Through 
the development of more efficient assays to monitor Ly fates in single-cell stromal assays and 
an improved sorting scheme, we identified human multilymphoid progenitors (MLP) as the 
earliest lymphoid differentiation precursor with concomitant lymphoid (T, B, NK) and 
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myelomonocytic potential (11, 12). Considerable uncertainty remains concerning the myelo-
erythro-megakaryocytic branch of human hematopoiesis since clonogenic CFC assays do not 
read out My, Er and Mk fates efficiently, nor contemporaneously making it difficult to account 
for all cells within phenotypically pure populations of CMPs and MEPs. A comprehensive 
analysis of human myelo-erythro-megakaryocytic development has not been undertaken and so 
it is really only by default that the standard model applies.  
Much of our understanding of the molecular basis of cellular differentiation and 
lineage commitment is derived from the assumptions implicit in the standard model. For 
example, simultaneous expression of molecular factors associated with My-Er-Mk lineages at 
low levels is considered to maintain CMPs as the origin of the common lineage for 
myelopoiesis (7). During restriction to GMPs and MEPs, progressive upregulation of particular 
lineage factors initiate feedforward and feedback molecular controls that lock-in a 
granulocyte/monocyte or a Mk-Er differentiation program. An important axiom that arises 
from this molecular view of the standard model is that cellular differentiation is gradual. 
However, transcriptional studies of highly purified or single cell murine HSPC has established 
that molecular programs corresponding to My-Er-Mk fates can directly emerge in multipotent 
cells, arguing that cellular differentiation is not gradual and that myeloid differentiation can 
occur without progressing through an intermediate CMP stage (4, 5, 13-17). Naik et al. have 
demonstrated that nearly half of the LMPP compartment is biased towards dendritic cell 
commitment, a lineage previously thought to come from the CMP to GMP route (15). 
Molecular factors associated with Mk-Er differentiation have been shown to be active in LT-
HSCs (13, 14), and prospective isolation of platelet-biased LT-HSCs strongly supports that this 
lineage is not derived from the CMP to MEP route (16). Whether molecular programs that 
regulate My-Er-Mk fates arise at the level of HSCs in humans is not known. It is important to 
understand where Er and Mk lineage branching occurs in the human hematopoietic hierarchy 
since these lineages comprise 99% of the cellular component of blood, and represent the bulk 
of the 300 billion blood cells that turnover daily in humans. Mapping the cellular origins of 
Er and Mk lineages in the human blood hierarchy represents a critical step to define the 
molecular basis of their fate commitment.  
The cellular roadmap describing the blood hierarchy has been built on two core 
experimental pillars: cell purification and clonal assays. Human studies reporting on sorting 
schemes for the myelo-erythroid progenitor hierarchy (CMPs, GMPs and MEPs) have often 
assumed that ‘marker-pure’ subsets are synonymous with ‘functionally-pure’ subsets (9). In 
other words, each cell within the purified subset possesses the same differentiation potential 
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(Fig. 1A, 1). This interpretation is primarily derived from clonogenic assessment of human 
CMPs, GMPs and MEPs using standard CFC assays. In CFC assays, purified CMPs typically 
generate My, Er or Mk colonies, GMPs give rise to My colonies only, and MEPs give rise to 
Er and/or Mks (9). Since CMPs displayed all lineage readouts whereas GMPs and MEPs did 
not, CMPs were interpreted as both marker-pure and functionally pure on the basis that the 
CFC assay was inefficient in being able to readout mixed differentiation potential. This 
reasoning underpins the basic bifurcating scheme of human CMPs to GMPs and MEPs. 
However, an alternate interpretation exists if we assume that the CFC assay is actually 
efficient. In this case, human CMPs are phenotypically homogenous (eg. marker-pure) but are 
functionally heterogeneous, consisting of diverse unipotent progenitors (Fig. 1A, 2). This 
contention could only be proven if a new sorting strategy is able to isolate, in functionally pure 
form, each type of the unilineage progenitor from the starting CMP population. To distinguish 
between the two alternatives, we need 1) a new sorting strategy for human myelo-erythroid 
progenitors, and 2) a more sensitive assay to assess mixed cell potential. Until both scenarios 
can be experimentally resolved, there is considerable uncertainty that clouds the classical view 
of the human hematopoietic hierarchy. We attempted to address both of these issues by 
developing a cell-sorting scheme and an optimized single cell assay to efficiently readout My, 
Er and Mk fates from putative multilineage cell types.   
 
RESULTS 
Previously defined human MPPs, CMPs and MEPs are heterogeneous  
We developed a cell-sorting scheme to examine the cellular heterogeneity within the CD34+ 
compartment of human blood. To a previous 7-parameter design (CD34, CD38, CD7, CD10, 
FLT3, CD45RA, Thy1) (11), we distinguished HSCs from MPPs by adding CD49f (18), 
identified Er-Mk progenitors by adding cMPL (CD110) (19, 20) (designated here as BAH1 to be 
consistent with the antibody clone used to detect this antigen) (21)(22) and CD71 (Transferrin 
receptor), and distinguished B-lymphoid committed progenitors from My progenitors such as 
GMPs in the CD45RA+ fraction by adding CD19. Upon evaluation in human fetal liver (FL), 
neonatal cord blood (CB) and adult bone marrow (BM), this 11 parameter cell-sorting layout 
provided a high resolution view of the phenotypic heterogeneity that exists within CD34+ cells 
across all developmental stages (Fig. 1B and fig. S1).   
 Many distinct cell types, such as HSCs, MPPs and MLPs, reside within the 
CD34+CD38-/lo (simplified as CD34+CD38- herein) stem cell-enriched compartment of 
human blood. We investigated whether CD71 or BAH1 expression corresponded to a known 
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cell type within this compartment in the FL. Approximately 10% of the FL CD34+CD38- 
expressed CD71, and half of these CD71+ cells also expressed BAH1 (fig. S1A, panel 2). 
Neither CD71 nor BAH1 was expressed on Thy1+ HSCs (fig. S2A) or on CD45RA+ MLPs (fig 
S2B) suggesting that these markers identify a different cell type within the MPP compartment. 
We redefined the current MPP compartment into three fractions (F1, F2 and F3) based on 
CD71 and BAH1 expression: MPP F1 cells were CD71-BAH1-, MPP F2 cells were 
CD71+BAH1- and MPP F3 cells were CD71+BAH1+ (Fig. 1B.vii). The expression of these 
molecules in the CD34+CD38- compartment was unexpected as the onset of Mk-Er lineage 
commitment according to the standard model occurs at the level of CMPs and MEPs that are 
found in the progenitor enriched CD34+CD38+ compartment. These data suggest that the 
detection of functional Er and Mk differentiation molecules on a subset of CD34+CD38- cells 
represents a unique branch point of this lineage within the multilineage compartment.  
 We next analyzed CD71 and BAH1 expression in the CD34+CD38+ progenitor 
compartment. Co-expression of FLT3 and the lymphoid antigen CD7 in FL CD34+CD38+ cells 
(fig. S2C) indicated that CD7 expression is not exclusive to lymphoid progenitors as reported 
previously in CB (23). Thus, CD7 expressing cells were not excluded in our sorting layout. In 
lieu of CD7, we used CD10 expression to exclude Ly progenitors (Fig. 1B.i; fig. S1, panels 6). 
In the FL CD34+CD38+CD10- cell compartment, FLT3 and CD45RA expression was used to 
identify commonly defined CMPs (FLT3+CD45RA−), GMPs (FLT3+CD45RA+), and MEPs 
(FLT3-CD45RA-) (Fig. 1B.iii; fig. S1, panels 7). Addition of CD71 and BAH1 to CMP and MEP 
populations uncovered phenotypic heterogeneity within these populations previously 
considered to be homogeneous. In line with the nomenclature we employed for the redefined 
MPP compartment described above, CMP and MEP compartments were also subdivided into 
three fractions with CD71 and BAH1 (F1: CD71-BAH1-, F2: CD71+BAH1-, F3: CD71+BAH1+; 
Fig. 1B.v-vii and fig. S1, panels 8,10). We repeated the same analysis in CB and adult BM to 
determine if CB and adult BM samples were similarly heterogeneous. All the major cell 
populations identified in the FL were also observed in CB and BM albeit at different degrees 
(table S1) indicating that the cellular heterogeneity uncovered by CD71 and BAH1 existed 
across all developmental stages (fig. S1B,C). Thus, previously defined human CMPs and MEPs 
that were considered homogeneous are in fact phenotypically heterogeneous when Er and Mk 
markers are applied. 
In summary, previously defined MPPs, CMPs and MEPs contain three distinct cellular 
fractions: F1s: lacking CD71 and BAH1; F2s: expressing CD71 but lacking BAH1; and F3s: 
expressing both molecules. A total of 33 distinct cellular classes from FL, CB and BM (11 per 
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developmental stage) were functionally interrogated to evaluate their lineage fate potential. To 
facilitate the review of the results below, a legend and complete phenotype is provided in Fig. 
1C and table S1.  
 
An optimized single cell assay for human My-Er-Mk progenitors  
To evaluate the functional potential of the cellular subsets identified above, we developed a 
single-cell in vitro assay that overcame the shortcomings of prior approaches to characterize 
human myeloid progenitors. An ideal assay would support the ability of single cells to 
simultaneously commit along My, Er and/or Mk fates as well as provide the conditions for 
their differentiated progeny to survive, propagate, and expand to permit detection. Standard 
MC assays do not strictly fulfill these criteria. For example, CD49f+ HSCs exclusively 
generated CFU-My in MC (fig. S3A and Supplementary text), yet single HSC sustain 
multilineage hematopoiesis in vivo (18). Also, the limited self-renewal potential of downstream 
progenitors makes them difficult to readout in vivo at clonal resolution, further highlighting 
the need to develop more sensitive in vitro methodology to assess the lineage potential of 
progenitors. We found that serum-free conditions supplemented with growth factors (SCF, 
FLT3, TPO, EPO, IL-6, IL-3, IL-11, GM-CSF, LDL) and stroma was highly efficient at 
assaying My, Er and Mk lineage potential from single CD34+ cells. Single cell derived clones 
were analyzed by flow cytometry after a 2 to 3 weeks culture period for Mk (CD41, CD42b), Er 
(GlyA), and My (CD14, CD15, CD33) cells. One example of the efficiency of this new assay 
comes from the analysis of CD49f+ HSC subset, which previously could not be read out in 
vitro as single cells (11). Under these new conditions, 77% of FL, 72% of CB and 48% of BM 
single CD49f+ HSCs were able to produce a clone (fig. S5A, left). Whereas only CFU-My were 
produced from HSC in MC, mixed clonogenic potential was now readily detectable with this 
assay. We used this assay to functionally map the lineage potential of all the newly defined 
CD34+ subsets from all three developmental time points.  
 
Unipotent progenitors dominate the blood hierarchy by adulthood  
To gain a global perspective of the functional differences in the blood hierarchy across 
ontogeny, we first combined all 11 CD34+ subsets from each developmental timepoint into one 
analysis of nearly 3000 single cells. Cloning efficiency was highest for FL and decreased 
gradually in CB and BM (FL – 74%, CB – 69%, BM – 55%; Fig. 2A). A simple stratification 
based on whether a single cell gave rise to one (unilineage) or more (multilineage) cell lineages 
revealed that 40% of FL CD34+ cells were multilineage compared to 27% of CB (p < 10-3, 
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Fisher’s exact test) and 18% of BM (p < 10-3, Fisher’s exact test) CD34+ cells (Fig. 2B). Thus, 
the ratio of multilineage to unilineage progenitors changes en bloc in development within the 
CD34+ population, a result that is independent of the complex marker scheme we used. 
To continue exploring the organizational relationships of progenitors across 
developmental timepoints, we investigated the proportion of multilineage to unilineage cells in 
the stem cell enriched (CD34+CD38-) and the progenitor enriched (CD34+CD38+) subsets. 
Within CD34+CD38- cells, FL and CB had a significantly higher proportion of multilineage 
cells compared to BM (FL vs. BM: 48.6% vs. 32.9%, p=0.0016; CB vs. BM: 46.1% vs. 32.9%, 
p=0.011; Fisher’s exact test). These proportional differences were more pronounced in the 
CD34+CD38+ progenitor compartment. In CD34+CD38+ cells, BM displayed three fold fewer 
multilineage cells compared to FL (FL: 28.8%; CB: 17.3%; 9.6%; p<0.0001, Fisher’s exact test) 
(Fig. 2C,D). Thus, both the stem and progenitor compartments from each developmental stage 
exhibited a proportional change in the percentage of multilineage cell types.  
Next we localized the differentiation stages most affected by the loss of multilineage 
progenitors. We reasoned that HSCs and subsets that lack differentiation markers CD71 and 
BAH1 (MPP F1, CMP F1 and MEP F1) would be enriched for cells with multilineage cell 
potential. Remarkably in FL, the ratio of multilineage to unilineage progenitors remained 
nearly constant across these subsets (Fig. 2E). By contrast, only HSC and MPP F1 subsets from 
CB and BM were highly enriched for multilineage cells, whereas their corresponding 
CMP/MEP F1s were comprised mostly of unilineage cell types (Fig. 2E; p < 0.05, Fisher’s 
exact test). In BM, virtually all multilineage cells were restricted to the CD34+CD38- stem cell 
compartment (Fig. 2E; p < 0.05, Fisher’s exact test). Hence, multilineage cell potential extends 
into the progenitor compartment in FL, but in BM, this potential is restricted to the 
CD34+CD38- stem cell compartment. In parallel, the progenitor compartment in BM is 
dominated by unilineage cell types.  
 
Mk-Er lineage branching in the blood hierarchy is developmentally defined  
To gain a detailed understanding of the differentiation potential of each progenitor subset 
identified by our sorting scheme applied to FL, CB and BM, we classified the functional 
potential of each single cell in our data set. Five distinct clonal outputs were classified: Mk 
only, Er only, My only, Mk/Er, and mixed (bipotent: Er/My or Mk/My; tripotent: Er/Mk/My) 
(Fig. 3A). The cloning efficiency of all subsets was high in MPP, CMP and MEP fractions (50-
80%; Fig. 3B; fig. S5A). 
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The highest percentage of mixed clones was found amongst the HSC subsets (FL: 
46.1%; CB: 49.3; BM: 33.3%; fig. S5A), except in BM where MPP F1 harbored higher mixed 
clone potential than HSC (51.9%), although this was not significant (BM HSC vs. MPP F1: 
p=0.1, Fisher’s exact test) (Fig. 2E). FL HSC and MPP F1 subsets had a statistically higher 
distribution of tripotent versus bipotent mixed clones compared to CB and BM HSC and MPP 
F1 (fig. S5B). In FL and CB, Mk-Er only clones appeared at the MPP F1 stage (FL: 29% of 
total; CB: 18% of total; Fig 3B, column1, row1). In BM, Mk-Er clones from MPP F1 were rare 
(~2%), rather 15% of all clones from this subset were Er-only. Mk activity from BM MPP F1 
was detected as a component of mixed clones that also contained My cells (further discussed 
below).  
We next interrogated the CD34+CD38+ compartment. Based on the classical view of 
the blood hierarchy, we would expect that true CMPs reside in a subset that lacks expression 
of differentiation markers such as CD71 and BAH1 (CMP F1). Only 15% of FL and CB CMP 
F1 clones were mixed, and no mixed clones from this subset were detected in BM (Fig. 3B, 
column 1, row2). Thus, we conclude that previously defined BM CMPs are not homogeneous 
for cells with multilineage My-Er-Mk potential, rather they heterogeneous and composed of 
subpopulations of unilineage My, Er and Mk progenitors (Fig 3B, row 2). To determine if the 
small percentage of mixed clones from FL and CB CMPs F1 population were derived from 
bona fide CMPs, we evaluated their My-Er-Mk potential. More than 80% of the mixed clones 
from FL and CB were bipotent (either Er/My or Mk/My) without concurrent Mk-Er-My 
potential (fig S5C). This data demonstrates that “bona-fide” CMPs are a rare component of the 
human hematopoietic tree, irrespective of developmental stage.  
MC and megacult colony assays indicated that subsets defined by CD71 and BAH1 
expression (F2 and F3) were highly enriched for Mk and Er activity (fig. S3A-D and 
Supplementary text). However, these assays cannot formally rule out that Er and Mk potential 
was derived from independent unilineage progenitors. We first tracked Mk-Er activity from 
single cells within the MEP subsets (MEP F1 through F3; Fig. 3B, row 3). MEP F1 was highly 
heterogeneous across developmental timepoints and comprised mostly of My progenitors in FL 
and BM (60% or more; Fig. 3B, column 1, row 3) that functionally resemble other F1 subsets 
from MPP and CMP. In CB and BM, ~70% of clones from MEP F2 were Er-only and 10% or 
less were Mk-Er clones (Fig. 3B, column 2, row3). MEP F2 is likely the subset within classical 
MEPs that gave rise to low-level Mk colonies in previous studies. MEP F3, the numerically 
dominant cell population within the classical MEPs, uniformly produced Er-only clones in FL, 
CB and BM (Fig. 3B, column 3, row3). Thus, classically defined MEPs are principally 
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comprised of Er-only progenitors when analyzed at single cell resolution and are not Mk-Er 
progenitors as previously thought.  
As only rare cells within the MEP fractions give rise to Mks, Mk potential must lie 
elsewhere in the blood hierarchy. We found that most Mk-Er activity came from the 
CD34+CD38- stem cell compartment (fig. S3C) and was particularly enriched within one of 
our newly defined MPP subsets (Fig. 3B, column2, row1). In FL, 60% of clones from MPP F2 
were of Mk-Er type and the remainder of this subset was composed of Mk-only or Er-only 
clones (Fig. 3B, column2, row1). Notably Mk activity was enriched but not restricted to the 
stem cell compartment in the FL. Since we did not find strong evidence for FL CMPs, we 
expect that FL Mk-Er progenitors arise from the stem cell compartment, specifically from 
MPP F2. In CB and BM, Mk-Er clones represented one-quarter of the total clonal output 
from this subset (Fig. 3B, column2, row1) and the rest were Er-only clones. In CB and more 
evident in BM, Mks predominantly emerged as part of mixed clones from HSCs and MPP F1, 
supporting the hypothesis that Mk branching occurs directly from a multipotent cell as 
predicted by the murine studies (5). These data suggest that both Mk-Er and multilineage 
potential are restricted to the stem cell compartment by adulthood, whereas unilineage fates 
predominate the progenitor compartment forming a simple ‘two-tier’ hierarchy, with few 
intervening oligopotent intermediates (Fig. 3D,E).  
 
In vivo analysis establishes hierarchical relationships between progenitor subsets 
In the blood hierarchy, cell types near the peak of the hierarchy, such as HSCs and MPPs, are 
rarer but possess higher proliferative potential. Lineage differentiation typically correlates with 
loss of proliferative potential. Although HSC and MPP subsets (F1-F3) are minor populations, 
they yielded 5-10X more cells compared to more abundant populations from the CMP and 
MEP subsets in vitro (fig. S6A).  
We then transplanted our cellular subsets in vivo and measured graft durability and 
size, as well as its lineage composition to establish the hierarchical relationships of our newly 
defined progenitor subsets. Due to tissue availability, only CB was used. As there are limited 
data on the engraftment capacity of human progenitors in the NOD-Scid-Il2rgnull (NSG) 
model, we first scrutinized the repopulations kinetics of human blood cells in this model. 
Using HSCs, we observed low-level lympho-myeloid as well as erythro-megakaryocytic 
engraftment as early as two weeks after transplant (fig. S6B-C) consistent with prior studies 
using NOD-Scid mice (24). We used two weeks as the standpoint from which to assess 
progenitor cell engraftment in vivo. One thousand CMP F1 cells and 3000 MEP F1 cells 
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generated a myelo-erythroid restricted that did not persist beyond two weeks (Fig. 4A, column 
3 and 5; fig. S6E). By contrast, 200 MPP F1 cells were able to sustain a robust and systemic 
multilineage graft (My-Er-Ly) beyond two weeks, consistent with the functional potential of 
true MPPs (Fig. 4A, column 1; Fig. 4B; fig. S6E) (18).  
To gather enough cell numbers for in vivo detection of Er-enriched subsets, we 
combined the F2 and F3 subsets from MPP, CMP and MEP for transplantation since they 
shared similar functional potential in vitro. The combined F2/F3 subsets from MPP, CMP and 
MEP all gave rise to prominent Er grafts in vivo, concordant with their in vitro potential (Fig. 
4A columns 2,4,6; fig S6D top panels). MPP F2/F3 cells were highly proliferative and 
generated a robust Er graft with only 400 transplanted cells (Fig. 4A, column 2), whereas CMP 
F2/F3 and MEP F2/F3 required 5 to 25 fold higher cell doses to generate an in vivo graft (Fig. 
4A, columns 4 and 6). Although platelets were difficult to detect in vivo from progenitor 
subsets, we did observe them in rare mice engrafted with either MPP F1 or MPP F2/3 cells 
(fig. S6C). Only MPP F2/F3 but not CMP F2/3 and MEP F2/3 were able to migrate 
systemically to non-transplanted bones and resemble the proliferative potential of MPP F1 (fig. 
S6E). When combined with the in vitro analyses of these subsets, these in vivo experiments 
support that Mk-Er enriched MPP F2/F3 are derived from HSCs or MPPs directly without 
invoking a lineage route via a CMP intermediate.  
 
A transcriptionally defined erythroid progenitor subnetwork in the CD34 hierarchy  
Lineage commitment coincides with the expression of key molecules that aid to ‘lock-in’ a 
differentiation program (25). Using low cell input RNA sequencing methodology (26), we first 
analyzed the expression profile of canonical lineage factors in bulk CB subsets. Genes 
associated with My specification such as MPO and CSF2RA (GM-CSFR) were highly expressed 
in GMPs, whereas genes associated with the Er lineage such as GATA-1 and EPOR, were 
highly expressed in F2/F3 subsets from MPP, CMP and MEP populations (fig. S7A). Mk 
differentiation markers, CD41 (ITGA2B) and CD42b (GP1BA), were highly expressed in MPP 
F2, in line with functional potential of this subset. These data provide an independent line of 
evidence that committed Mk progenitors reside within the stem cell compartment. Low-level 
expression of CD41 and CD42b was also detected in MPP F3 and MEP F2 consistent with the 
residual Mk activity from these CB subsets (fig. S7A).  
Unsupervised hierarchical clustering and principal component analysis of the entire 
data set revealed two major molecular subgroups: those with Er-enriched potential (MPP, 
CMP and MEP F2/F3s), and another with multilineage (HSC, MPP F1) or My-enriched 
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potential (CMP F1 or MEP F1; fig. S7B). F2 and F3 subsets within MPP, CMP and MEP 
populations clustered together, suggesting these pairs are more closely related within each 
broader compartment (fig. S7Bi). Due to their close transcriptional and functional relationship, 
we merged F2 and F3 subsets from MPP, CMP and MEP subsets to compare global 
transcriptional differences amongst these Er-enriched subsets. We found that 230 genes were 
differentially expressed between MPP (F2/F3) versus CMP (F2/F3), and 52 genes between 
CMP (F2/F3) versus MEP (F2/F3). These differentially expressed genes were highly enriched 
in cell cycle, and DNA replication and metabolic processes, and coincide with the extensive 
proliferation that Er progenitors undergo during specification (fig. S7C). These data reinforce 
the idea that the close functional relationship between Mk-Er and Er enriched subsets is likely 
due to shared molecular programs.  
Molecular heterogeneity amongst single cells within a purified subset is commonly lost 
in a population-level analysis. We tracked the expression of key lineage factors amongst single 
cells in our progenitor subsets. Only FL and BM were used in this experiment since they 
represent the two ends of the development timepoints used in this study. In both FL and BM, 
single cells from F2 and F3 from MPP, CMP and MEP displayed a dominant Er gene 
expression program often co-expressing both GATA1 and EPOR genes in the same cell (Fig. 5A, 
fig. S7D). Our sorting method can essentially resolve the Er-committed progenitors within the 
CD34+ hierarchy. We observed that GATA1 expression was present amongst most single cells 
in MPP F2 and MPP F3, but EPOR expression was only present in a subset of GATA1 positive 
cells (Fig. 5A,B). Since GATA1 precedes EPOR expression in Er differentiation, MPP F2/F3 
cells represent the earliest erythroid differentiation precursor in the human blood hierarchy. 
The percentage of single cells that co-expressed GATA1 and EPOR increased in proportion 
amongst F2 and F3 subsets from MPP, CMP and MEP in both FL and BM (Fig. 5B). These 
molecular factors are considered a surrogate of the degree of Er differentiation (Fig. 5B). When 
considered jointly with our in vitro and in vivo analyses, these subsets are already Er specified 
but vary mostly in their proliferative potential. We hypothesize that these subsets compose a 
hierarchical subnetwork of Er progenitors within the CD34+ compartment (Fig. 5C). A 
candidate network map is shown in Fig. 5C. Since erythrocytes comprise nearly 99% of all 
blood cells, this network may offer a high degree of flexibility to synthesize erythrocytes under 
homeostatic and emergency erythropoiesis without HSC input.  
 
Dramatic loss of Er progenitors compared to My progenitors in a hematologic condition 
of HSC deficiency 
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Recent HSC fate-mapping analyses in mouse have provocatively shown that progenitors and 
not HSCs, are fundamental for on-going hematopoiesis under homeostatic conditions (27, 28). 
Physiological studies to experimentally test this question are not possible in normal human 
subjects. However, certain disease states permit a glimpse into the consequences of HSC loss 
on progenitors and may shed light on the role of HSCs in human blood synthesis under non-
transplant conditions. In aplastic anemia (AA), HSCs are damaged likely due to an 
autoimmune response and unable to contribute to on-going hematopoiesis (29, 30). This effect 
seems to be specific to HSCs as all mature blood lineages are depressed in AA (31-33). We 
examined the progenitor hierarchy in three cases of AA by applying our sorting scheme (Fig. 
6). Consistent with previous reports, the proportion of CD34+ cells within the overall 
mononuclear cell (MNC) pool was significantly lower in AA compared to normal BM (0.1% vs. 
4.2%, p<0.0001, t-test) (Fig. 6B) (31, 32). The CD34+CD38- stem cell compartment in AA 
patients was more significantly depleted compared to the CD34+CD38+ progenitor 
compartment (Fig. 6A, left column; Fig. 6C,D). Moreover, HSCs and MPPs were virtually 
undetectable in the residual CD34+CD38- compartment, confirming that HSCs are specifically 
lost in this clinical condition (Fig. 6A, column 2), at least at the phenotypic level. Despite the 
loss of phenotypic HSCs, the CD34+CD38+ compartment was detectable in all cases. We 
quantified the subsets within the CD34+CD38+ compartment to determine if all cell types are 
indiscriminately affected. Based on our single cell functional readouts, we grouped progenitors 
enriched for myeloid (CMP F1, MEP F1, GMP) and erythroid (CMP F2/F3, MEP F2/F3) 
differentiation potential to increase the power of the analysis due to relative loss of CD34+ 
cells in AA. Despite significant depletion of HSCs, the percentage of myeloid progenitors was 
stable compared to normal BM (Fig. 6E). In contrast, erythroid progenitors were significantly 
lost, like HSCs, in all three patients analyzed (Fig. 6F, p<0.0001, t-test). These results suggest 
that on-going erythropoiesis is more reliant on HSC input compared to myelopoiesis. Although 
we cannot rule out a specific Er lineage defect in AA, the pan-lineage deficiencies observed in 
AA likely rule out this possibility and support the idea that the Er progenitor loss is most 
likely a repercussion of HSC depletion. Since all HSC types (LT/IT/ST) seem to be broadly 
lost in AA, our results cannot distinguish which type of HSC is crucial to maintain 
erythropoiesis. Recognizing that hematopoiesis in AA is not normal, the revised hierarchy 
model predicted from our experimental data does appear to have physiological relevance in the 
human setting.  
 
 
DISCUSSION  
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Our study challenges the current view that human blood development occurs progressively 
through a series of multipotent, oligopotent and then unilineage progenitor stages. By 
subjecting the classically defined progenitor subsets to a sorting scheme that efficiently 
resolved My, Er and Mk lineage fates, combined with single-cell functional analysis, we made 
two findings. First, we found that the cellular hierarchy of human blood is not identical across 
development. In FL, oligopotent progenitors with My-Er-Mk and Er-Mk activity were a 
prominent component of the hierarchy. By contrast, the BM was dominated by unilineage 
progenitors with primarily My or Er potential. This shift in progenitor classes demarcates a 
fundamental readjustment in the blood hierarchy during in utero to adulthood timepoints. The 
absence of oligopotent intermediates that become gradually restricted to unilineage progenitors 
in BM cannot be reconciled under the standard model of HSC differentiation. Instead, our 
data support a hierarchy composed mainly of two-tiers in adults: a top-tier which contains 
multipotent cells such as HSCs and MPPs, and a bottom-tier composed of committed 
unipotent progenitors (Fig. 7). We cannot formally rule out the presence of a highly transient 
adult CMP-like progenitor stage that exists when multipotent cells differentiate into unipotent 
progenitors, however our in vitro and in vivo assays surveyed large cell numbers (~3000) and 
such a progenitor was not detected. If lineage restricted cell types able to generate a subset or 
full spectrum of myeloid cells do exist in the stem cell compartment of adult marrow, they 
most probably represent the murine counterparts of myeloid-bias or myeloid-restricted HSC 
subtypes (5, 34). Second, the origins of the Mk lineage branch change from FL to BM. In FL, 
Mk progenitors were enriched but not restricted to the stem cell compartment whereas in BM, 
the Mk lineage was closely tied to the fate of multipotent cells. These data are not consistent 
with the principal tenet of the standard model that My, Er and Mk lineages originate from a 
common lineage progenitor such as CMP.  
Historically, the first major lineage bifurcation step in the blood hierarchy was 
considered to be the segregation of myeloid (My-Er-Mk) and lymphoid fates, with CMPs 
occupying the lineage fork that gives rise to the entire myeloid arm. The co-emergence of My, 
Er and Mk lineages was central to the description of CMPs. Our results reveal that the 
originally defined CMPs are highly heterogeneous, primarily composed of unipotent My or Er 
progenitors with little Mk activity. In the absence of CMPs, how can the origins of lineage-
restricted progenitors such as GMPs and MEPs be reconciled? Our previous clonal analysis 
suggested that myelomonocytic lineages originate from MLPs, which we suspect is the most 
probable precursor of GMPs due to their shared functional and transcriptional profiles (11, 12, 
35). In this study, we found that GATA-1 positive Mk-Er committed progenitors exist in the 
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stem cell compartment suggesting that MEPs are derived from multipotent cells. In the 
murine bone marrow niche, up to a quarter of LT-HSCs lie directly adjacent to Mks (36-38). 
Mks play a dual role in HSC regulation. Under normal conditions, Mk-HSC contact is 
essential to preserve the quiescent nature of adult LT-HSCs. After myeloablation, this effect is 
temporarily abrogated and Mks secrete growth factors that permit HSCs to expand (37). Thus, 
direct differentiation of Mks from HSCs may represent a physical mechanism to regulate blood 
stem cell functionality in the niche. Overall, the first major bifurcation step in blood 
differentiation is far more complex than a simple segregation of myeloid and lymphoid 
lineages. In humans, we suspect this first step splits the Mk-Er lineage from the 
myelomonocytic lineage that co-segregates with the lymphoid fate (11). Why the 
myelomonocytic lineage but not the granulocytic lineage is tied to the lymphoid fate will be a 
critical area of future investigation (39, 40). The ability to isolate developmental populations 
reported here provides a critical experimental framework to facilitate such studies in humans.  
Our data may also have implications for our understanding of lineage specification at 
the molecular level. vWF, a key molecular marker strongly associated with Mk differentiation, 
was expressed in a subset of BM HSCs and may identify an HSC subtype primed for platelet 
production as shown in mouse (16). Molecular factors involved in Mk (vWF), Er (EPOR) and 
My (CSF2RA) differentiation were expressed in small pockets of single cells from 
undifferentiated cells, like BM HSCs, in a near mutually exclusive manner. This is consistent 
with the notion that TFs associated with myeloid lineage specification are individually but not 
simultaneously primed at the level of stem cells. It is difficult to preclude that this type of 
molecular heterogeneity reflects impurities in human HSC isolation. However, analysis of 
purer murine HSC compartments supports that molecular factors associated with lineage 
commitment is stochastically activated at the level of HSCs (16, 17). Maintenance of a 
multipotent state is thought to occur via low-level lineage priming where TFs of different 
lineages are co-expressed in the same cell. In this model, commitment towards a particular 
lineage occurs by the mutual antagonism of these TFs where one TF eventually wins, locking-
in a differentiation program. However, the near mutually exclusive expression of vWF, CSFR2A 
and EPOR in BM HSCs does not agree with this logic. The hypothesis that lineage 
commitment occurs in the absence of a coordinated differentiation program (17, 25, 41) is more 
consistent with our data.  
 Ultimately, a better understanding of normal blood differentiation programs will be 
critical to decipher how such programs go awry in disease. Indeed in AA, we observed that 
Mk-Er progenitors are lost alongside HSC, but the My progenitor pool can continue to persist. 
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Recent evidence from murine in situ tracking experiments showed that My progenitors can be 
sustained long term without contribution from HSCs (27, 28). If human My progenitors are 
similarly long-lived, they would have a higher probability of acquiring mutations that could 
lead to clonal expansion and eventual My lineage leukemias. The short-lived nature of Mk-Er 
progenitors and their dependency on HSC input reduces their probability of accumulating 
enough mutations leading to leukemia. Clinical evidence that acute leukemia of the Mk and 
Er lineages are extremely rare compared to My leukemia is consistent with this idea. Our work 
on AA highlights one example of the clinical utility of a high-resolution developmental 
roadmap of normal hematopoiesis. The adaptable nature of our new sorting scheme should 
similarly inform on other hematological conditions.  
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FIGURE LEGENDS 
Figure 1: CD71 and BAH1 expression uncover cellular heterogeneity in currently 
defined populations of human MPPs, CMPs and MEPs. (A) A review of classic 
interpretations from previous work using CFC assays to measure the clonal outputs from a 
sorted (‘marker pure’) population of cells. In scenario 1, each cell within a marker-pure 
population has the potential to give rise to three functional outputs (a, b and c), but only gives 
rise to one of them in the assay. Under this condition, diverse functional outputs from a 
marker-pure population are interpreted to be derived from a functionally homogeneous 
population of a multilineage cells. In the alternate scenario 2, a marker pure population is 
comprised of three distinct unipotent cell types that give rise to lineages a, b and c 
independently. Both these scenarios can be reconciled with a better assay (right – top) or better 
markers (right – bottom). (B) The gating scheme of defining MPPs (CD34+CD38-Thy1-
CD45RA-CD49f-), CMPs (CD34+CD38+CD10-FLT3+CD45RA-) and MEPs 
(CD34+CD38+CD10-FLT3CD45RA-) from a representative human FL sample is shown (black-
dashed arrows). Each subcompartment was further divided into F1 (CD71-BAH1-), F2 
(CD71+BAH1-) and F3 (CD71+BAH1+) (blue-dashed arrows). Full gating scheme for FL, CB 
and BM CD34+ cells is presented in fig. S1. (C) Summary of the new subsets used in this 
study.  
Figure 2: Assessment of multilineage and unilineage cell potential of single CD34+ cells 
from FL, CB and BM. (A-D) Single cells from subsets defined in Fig 1C were deposited by 
fluorescence-activated cell sorting (FACS) and cultured for several weeks. Emergent clones 
were analyzed by flow cytometry for My, Er and Mk lineages (Fig. 3A). To gain a global 
perspective of the functional differences between FL, CB and BM, subsets were combined into 
one analysis of CD34 cells (A&B) or stem (CD34+CD38-) and progenitor (CD34+CD38+) cell 
compartments (C&D). A single cell was defined as multilineage (black) when it gave rise to 
more than one lineage (any two of My, E or Mk), and unipotent when it gave rise to one 
lineage (My or E or Mk) (B&D). Overall cloning efficiency is shown in grey (A&C). (E) 
Distribution of multilineage and unilineage cell potential from populations that lack CD71 and 
BAH-1 (F1s) expression (shown by increasing differentiation: HSC > MPP F1 > CMP F1 > 
MEP F1). Asterisks indicate significance based on Fisher’s exact test (* p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001). 
Figure 3: Lineage analysis of single cell clones from subfractions of MPP, CMP and 
MEP populations. (A) Single cell clones were analyzed by flow cytometry and binned into 5 
distinct lineage outcomes. Erythroid clones were defined as GlyA+ only (Er only). Myeloid 
clones were identified as GlyA-CD41-, but CD45+CD11b+ (My only). Erythroid-megakaryocyte 
clones were defined as GlyA+ and CD41+ but negative for CD11b (Er/Mk). Mix clones were 
defined My and Er/Mk (column 4), or My, Er and Mk (column 5). (B) Cloning efficiency and 
lineage outcomes of single cells from newly defined MPP, CMP and MEP fractions (F1s, F2s 
and F3s) from FL, CB and BM. (C) Total Mk output (CD41+) from all newly defined subsets 
from FL, CB and BM. Bars indicate mean ± standard error. Total number of independent 
experiments: n=3, 6 and 4 for FL, CB and BM respectively. (D) 3-D summary of lineage 
outputs (My, Er and Mk) from all cellular subsets in FL, CB and BM presented in Fig. 3B. (E) 
Pictorial depiction of the predominant lineage outcomes from stem (CD34+CD38-) and 
progenitor (CD34+CD38+) cell compartments in FL and BM data.  
Figure 4: In vivo potential of progenitor subsets. (A) Freshly sorted populations from CB 
were intrafemorally transplanted into sublethally irradiated NOD-scid-IL2Rgnull (NSG) mice. 
Bone marrow from injected femur and non-injected bones were analyzed by flow cytometry two  
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weeks after transplant. Average transplanted cell dose in the inset of the flow plot. Top row 
indicates Er engraftment (GlyA+CD71+). Bottom row indicates total human leukocyte 
engraftment (CD45+). B-lymphoid cells and My cells were detected using CD19 and CD33, 
respectively. (B) Kinetic analysis of engraftment from progenitor subsets. Mean levels of Er 
and total human cell engraftment are shown.  
Figure 5: Single cell gene expression profiling of FL and BM subsets. (A) Single cells 
from FL (top) and BM (bottom) subsets were sorted and analyzed for expression of genes 
associated with My, Er and lymphoid (Ly) lineages (shown on right) on the Fluidigm platform. 
My, Er or Ly gene clusters are shown as dashed boxes. (B) Percent of single cells that co-
express GATA1 and EPOR in F2 and F3 from MPP, CMP and MEP subsets. BM and FL F2 
and F3 subsets were combined in this analysis. (C) A theoretical subnetwork of Er progenitors 
within the CD34+ compartment.  
Figure 6: Analysis of My and Er progenitors in patients with aplastic anemia. (A) To 
examine the consequences of HSC loss on progenitor subsets, BM cells from three aplastic 
anemia (AA) patients and normal controls were subjected to the new sorting design shown in 
Fig. 1B. Representative flow plots from a single AA case and a control are shown. (B) 
Quantification of total CD34+ cells as a fraction of mononuclear cell (MNC) pool from 
controls (empty bars) versus AA (filled bars). (C-D) The CD34+ subset from controls and AA 
was further sub-divided into the stem (CD34+CD38-) and progenitor (CD34+CD38+) cell 
compartments. (E) Analysis of My enriched subsets (CMP F1, MEP F1 and GMP) in controls 
and in AA. (F) Analysis of Er enriched subsets (CMP F2/F3, MEP F2/F3) in controls and in 
AA. Bars indicate mean ± standard error from 3 controls and 3 cases of AA. Asterisks indicate 
significance based on t-test (** p<0.01, **** p<0.0001). 
Figure 7: A model of the changes in human My-Er-Mk differentiation that occur across 
developmental timepoints. Graphical depiction of My-Er-Mk cell differentiation that 
encompasses the predominant lineage potential of progenitor subsets; the standard model is 
shown for comparison. The redefined model proposes a developmental shift in the progenitor 
cell architecture from the fetus where many stem and progenitor cell types are multipotent to 
the adult where the stem cell compartment is multipotent, but the progenitors are unipotent. 
The grayed planes represent theoretical tiers of differentiation. 
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SUPPLEMENTARY FIGURE AND TABLE LEGENDS 
Figure S1: Complete cell sorting scheme of HSC and progenitor cell subsets.  
(A-C) Representative plots of CD34+ selected FL (A), CB (B) and BM (C) subjected to an 11 
parameter flow sorting scheme are shown. Dead cells were excluded using propidium iodide 
(not shown). Cells were subsequently subdivided into CD34+CD38- and CD34+CD38+ 
compartments (Panel 1).  Within the CD34+CD38- compartment, CD71 and BAH1 expression 
defined Thy1- F1 and F2 (Panel 2). Cells that lacked CD71 and BAH1 expression in the 
CD34+CD38- compartment (double negative gate in Panel 2) were further gated for HSCs and 
MPPs (MPP FI) on the basis on Thy1 and CD49f (Panels 3-5). Within the CD34+CD38+ 
compartment, CD10– cells (Panel 6) were fractionated according to FLT3 and CD45RA 
expression to define classical CMPs, GMPs and MEPs (Panels 7). CMPs and MEPs were 
further subfractionated according to CD71 and BAH-1 expression (Panels 8,10: F1, F2, F3). 
CD19 expression was used to exclude CD45RA+ B-cells from the GMP population (Panels 9). 
Blue arrows indicate the flow of substructure during sorting.  
 
Figure S2: Assessment of the markers used to establish newly defined MPP, CMPs, and 
MEPs. (A) Thy1+ (left) (used to identify HSCs) were gated cells were analyzed for CD71 
(middle) and BAH1 (right) expression. A representative flow plot from BM is shown. (B) 
Similar to A, CD34+CD38- cells were analyzed for CD45RA and CD71 expression to 
determine if these markers are expressed in a mutually exclusive manner. Two distinct 
biological FL samples are shown in A and B. (C) Within FL CD34+CD38+ compartment, 
CD7+ cells (left) express high levels of myeloid differentiation marker (FLT3, right). FLT3 
expression in CD10+ cell was used as a negative control (right). Black arrows depict gating 
scheme. (D) Backgating of CD71+BAH1- (F2s) and CD71+BAH1+ (F3s) fractions against 
class`ical CMP, MEP, and GMP populations.  
 
Figure S3: Methylcellulose (MC) and MegacultTM colony assays for all CD34+ subsets in 
FL, CB and BM. (A) For each colony assay 100 sorted cells were plated in duplicates. Cloning 
efficiency per 100 plated cells for each colony type is shown as a percentage of total plating 
efficiency. Colonies from MC were scored for colony forming units (CFU) 14 days after plating. 
(B) High proliferative potential (CFU-HPP) colonies were scored as colonies that were >1000 
cells. (C) MegacultTM colonies (CFU-Mk) were assessed 10 days after plating using GPIIb/IIa 
specific antibody. CFU-Mk will appear red in the assay and can be distinguished from non 
CFU-Mk (blue). (D) CFU-Mk were segregated according to size established in MegaCultTM 
manual (Stem cell Technologies). Residual colonies (<20 cells) are not included in (C) as this 
did not pass the a priori threshold for the analysis. However, we suspect that these residual 
small colonies are likely what has been observed in classical CMP and MEP compartments 
from previous studies using various methodologies. For that reason, analysis of small CFU-Mk 
(<20 cells) are shown in fig. S4D. Bars indicate mean at least three biological replicates ± 
s.e.m. 
 
 
Figure S4: Assessment of colony size from CD34+ progenitor subsets in FL and BM. (A) 
To determine the average colony size from each subset assayed in the MC assay from fig. S3A, 
duplicate culture plates from each cell population of FL and BM were harvested and cells 
counted using ViCell XR. Cell counts were subsequently divided by the total number of CFU 
to obtain the average colony size. (B) Fold difference in colony size from A between FL and 
BM. (C) Representative flow cytometry analysis of CFU colonies from FL MEP F3. Due to low 
hemoglobinization, these colonies were morphologically defined to be myeloid (CFU-My), flow 
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cytometry analysis clearly demonstrates that these cells express GlyA and are indeed erythroid 
cells. Bars indicate mean of at least three biological replicates ± s.e.m. 
 
Figure S5: Lineage outcomes of single cell clones from HSC, MPP and GMP from FL, 
CB and BM. In stroma based assay (A) Lineage potential and colony distribution of single 
cells clones from HSC and GMP subsets from FL, CB and BM. Examples of various clone 
types (Mix, My, Mk, E/Mk/E) are shown in Fig. 3A. (B-C) Distribution of double (double: 
Er/My or Mk/My) and triple mixed (triple: Er/My/Mk) colonies from HSC/MPP F1 and CMP 
F1 (C). 
 
Figure S6: Kinetics of engraftment of CB HSC subset into NSG mice.  
(A) Relative proliferative capacity of newly identified FL and BM subsets. The size of the circle 
represents the proliferative potential from colony assays. The clonal output of each subset is 
depicted within each circle. (B) Few hundred freshly sorted CD49f+ HSCs from CB were 
transplanted into large cohort of female NSG recipients. Three to four mice were sacrificed at 
multiple timepoints (2, 4, 8, 16, 24 wk) after transplant and analyzed for all major human cell 
lineages in the injected femur (left) and non-injected bones (right) using flow cytometry. Total 
human cell engraftment and lineage assessment (B-lymphoid - CD19; total myeloid - CD33+; 
granulocyte – CD15+CD14-; monocyte – CD14+; erythroid – GlyA+CD71+) is represented both 
as a percentage (column 1) and in absolute numbers (column 2). (C) Temporal analyses of total 
human cell engraftment (CD45+, left) and human platelets (CD41+CD42b+) from HSC. (D) 
Human platelets in the peripheral blood of NSG mice were detected in rare recipients at 2 
weeks post-transplant from MPP F1 and MPP2/3. A typical negative control and positive 
control are shown as a comparison. (E) Total Er (GlyA+, top) and human cell engraftment 
(CD45+, bottom) from cell subsets from injected femur and non-injected bones two weeks after 
transplant. Bars indicate mean ± standard error from two independent experiments (n = 3 – 21 
mice). 
 
Figure S7: Gene expression analysis of CB subsets using RNA sequencing. Cells of twelve 
CB subsets in duplicates were sorted and subjected to SMARTseq protocol for low input RNA 
sequencing. Sequence alignment was conducted using STAR and bam files were analyzed for 
expression using cufflinks package. (A) Gene expression analysis (FPKM) of lineage factors 
associated My (MPO, CSF2RA), Mk (CD41 and CD42b), Er (GATA1, EPOR). Housekeeping 
genes, PGK1 and GAPDH, were used as a control. FPKM – fragments per kilobase of exon per 
million fragments mapped). (B) Unsupervised clustering (i) and principal component analysis 
(ii) of all CB subsets. (C) Go analysis using DAVID of differentially expressed genes from Er 
biased subsets (MPP F2/3, CMP F2/3, MEP F2/3).These differentially expressed genes were 
highly enriched in cell cycle, and DNA replication and metabolic processes. (D) Additional 
populations for single cell fluidigm analysis from Fig. 5A (FL MPP F3, FL CMP F3 and BM 
MPP F1).  
 
Table S1: List of flow sorted subsets used in this study. Complete phenotype and their 
percentage (± s.e.m) within the CD34+ fraction are shown.	  
 
 
